Skip to main content
. 2019 Feb 5;12:235–245. doi: 10.1016/j.omto.2019.01.007

Figure 1.

Figure 1

Cell Cycle of BCPAP, K1, and BHP2-7 Treated with 0.05 μM Panobinostat and 0.1 μM Dabrafenib/2.5 μM Selumetinib Individually, in Combination, or with DMSO for 24 h

In BCPAP and K1 cells treated with panobinostat or MAPKi (dabrafenib or selumetinib) alone, the proportion of G1-phase cells was more than that in the DMSO control group. More cells were arrested in G1 phase when cells were treated with panobinostat in combination with MAPKi (dabrafenib or selumetinib). The number of G1 cells in panobinostat-treated BHP 2-7 cells was more than that in DMSO control; proportions of G1 cells in MAPKi (dabrafenib or selumetinib)-treated BHP 2-7 cells were not significantly different from that in the DMSO control, and the number of G1 cells in the combined treatment group was not significantly different from that in the panobinostat-treated group.